Concepedia

Publication | Open Access

Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma

DOIFull Paper Access

24

Citations

22

References

2019

Year

Takahiro Akahori, Masayuki Sho, Hiroaki Yanagimoto, Sohei Satoi, Minako Nagai, Satoshi Nishiwada, Kenji Nakagawa, Kota Nakamura, Tomohisa Yamamoto, Satoshi Hirooka,
The Oncologist

Abstract

SOXIRI is considered a promising and well-tolerated regimen in patients with unresectable PDAC.

References

YearCitations

Page 1